Osimertinib in EGFR T790M Advanced NSCLC: Analysis of Uncommon/Complex EGFR Mutations in a Real-World Study (ASTRIS)

被引：4
|
作者：
Cheema, P. [1 ]
Passaro, A. [2 ]
Martin, C. [3 ]
Tiseo, M. [4 ]
Park, K. [5 ]
Chang, G. [6 ,7 ,8 ]
Hu, Y. [9 ]
Cho, B. C. [10 ]
Miranda, M. [11 ]
Fernandes, A. [12 ]
Freitas, H. [13 ]
机构：
[1] Univ Toronto, Sunnybrook Odette Canc Ctr, William Osler Hlth Syst, Toronto, ON, Canada
[2] European Inst Oncol Irccs, Ieo, Div Thorac Oncol, Milan, Italy
[3] Inst Alexander Fleming, Dept Oncol, Buenos Aires, DF, Argentina
[4] Univ Hosp Parma, Med Oncol Unit, Parma, Italy
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol, Seoul, South Korea
[6] Taichung Vet Gen Hosp, Dept Internal Med, Div Chest Med, Taichung, Taiwan
[7] Taichung Vet Gen Hosp, Fac Med, Sch Med, Taichung, Taiwan
[8] Natl Yang Ming Univ, Taichung, Taiwan
[9] Hubei Canc Hosp, Dept Oncol, Wuhan, Hubei, Peoples R China
[10] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[11] Astrazeneca, Biometr & Informat Sci, Cambridge, England
[12] Astrazeneca Us, Gaithersburg, MD USA
[13] AC Camargo Canc Ctr, Clin Res Unit, Sao Paulo, Brazil
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
NSCLC; EGFR; Osimertinib;
D O I：
10.1016/j.jtho.2019.08.1844
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.14-59
引用
收藏
页码：S854 / S854
页数：1
相关论文
共 50 条
  • [31] First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
    Ji, W.
    Jiang, D.
    Zhang, J.
    Zhang, H.
    Wang, Q.
    Cang, S.
    Li, X.
    Tan, J.
    Xiang, Y.
    Li, X.
    Liu, A.
    Lu, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1693 - S1693
  • [32] Sequential Afatinib and Osimertinib in Patients With Advanced EGFRm plus NSCLC and Acquired T790M: The Real-World UpSwinG study
    Popat, S.
    Jung, H. A.
    Lee, S. Y.
    Hochmair, M. J.
    Lee, S. H.
    Escriu, C.
    Lee, M. K.
    Migliorino, M. R.
    Lee, Y. C.
    Girard, N.
    Daoud, H.
    Marten, A.
    Miura, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1120 - S1121
  • [33] Mechanisms of acquired resistance to osimertinib in advanced NSCLC with EGFR T790M mutation (LOGIK1607)
    Yamaguchi, Masafumi
    Osoegawa, Atsushi
    Nakamura, Tomomi
    Morinaga, Ryotaro
    Tanaka, Kentaro
    Kashiwabara, Kosuke
    Miura, Takashi
    Suetsugu, Takayuki
    Taguchi, Kenichi
    Nabeshima, Kazuki
    Kishimoto, Junji
    Sakai, Kazuko
    Nishio, Kazuto
    Sugio, Kenji
    CANCER SCIENCE, 2021, 112 : 567 - 567
  • [34] Association between BIM Deletion Polymorphism and Efficacy of Osimertinib in Advanced EGFR T790M NSCLC Patients
    Li, X.
    Zhang, D.
    Wang, R. Z.
    Li, B.
    Guo, M.
    Zou, B.
    Yu, J.
    Wang, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E87 - E87
  • [35] A phase II study to assess the efficacy of osimertinib in patients with EGFR MT(+)T790M(-) NSCLC
    Hayakawa, Daisuke
    Takeda, Masayuki
    Shimokawa, Mototsugu
    Nakamura, Atsushi
    Nosaki, Kaname
    Watanabe, Yasutaka
    Kato, Terufumi
    Tanaka, Hiroshi
    Takahashi, Toshiaki
    Oki, Masahide
    Tachihara, Motoko
    Fujimoto, Daichi
    Yamaguchi, Kakuhiro
    Hayashi, Hidetoshi
    Yamamoto, Shoichiro
    Iwama, Eiji
    Azuma, Koichi
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    ANNALS OF ONCOLOGY, 2023, 34 : S1387 - S1387
  • [36] Successful treatment with osimertinib for leptomeningeal carcinomatosis from NSCLC with the EGFR T790M mutation
    Yoshimura, Naruo
    Takahashi, Hidenori
    Kurosawa, Emiko
    Tanaka, Akiko
    Ebina, Masahito
    Ohrui, Takashi
    ANNALS OF ONCOLOGY, 2019, 30 : 139 - 139
  • [37] EGFR TKIs in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG)
    Miura, S.
    Hsia, T-C.
    Hung, J-Y.
    Jung, H. A.
    Shih, J-Y.
    Park, C-K.
    Lee, S. H.
    Okamoto, T.
    Ahn, H. K.
    Lee, Y. C.
    Sato, Y.
    Lee, S. S.
    Mascaux, C.
    Daoud, H.
    Maerten, A.
    Popat, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S967 - S968
  • [38] Real-world outcomes of osimertinib in Peruvian patients with advanced NSCLC with EGFR T790M-positive: A multi-institutional experience
    Galvez-Nino, Marco
    Roque, Katia
    Namuche, Fernando
    Ruiz, Rossana
    Paitan Amaro, Victor
    Coello, Roberto
    del Pilar Cabrera, Maria
    Maco, Lorenzo
    Carlos Ezquerra, Juan
    Perez Roca, Rodolfo
    Coanqui, Ofelia
    Valdivieso, Natalia
    Olivera Hurtado de Mendoza, Mivael
    Aguilar Cartagena, Alfredo
    Mas, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example
    Wei, Bing
    Zhao, Chengzhi
    Li, Jun
    Zhao, Jiuzhou
    Ren, Pengfei
    Yang, Ke
    Yan, Chi
    Sun, Rui
    Ma, Jie
    Guo, Yongjun
    MOLECULAR ONCOLOGY, 2019, 13 (05) : 1226 - 1234
  • [40] Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients
    Remon, Jordi
    Caramella, Caroline
    Joelet, Cecile
    Lacroix, Ludovic
    Lawson, Andrew
    Smalley, Sarah
    Howarth, Karen
    Gale, Davina
    Rosenfeld, Nitzan
    Green, Emma
    Plagnol, Vincent
    Planchard, David
    Bluthgen, Maria
    Gazzah, Annas
    Pannet, Chloe
    Nicotra, Claudio
    Soria, Jean-Charles
    Besse, Benjamin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1254 - S1255
12345